Prognostic Impact of Active Mechanical Circulatory Support in Cardiogenic Shock Complicating Acute Myocardial Infarction, Results from the Culprit-Shock Trial.
Hans-Josef FeistritzerSteffen DeschAnne FreundJanine PoessUwe ZeymerTaoufik OuarrakSteffen SchneiderSuzanne de Waha-ThieleGeorg FuernauIngo EitelMarko NocJanina StepinskaKurt HuberHolger ThielePublished in: Journal of clinical medicine (2020)
In the CULPRIT-SHOCK trial, active MCS devices were used in approximately one fifth of patients. Patients treated with active MCS devices showed worse outcome at 30 days and 1 year.
Keyphrases
- acute myocardial infarction
- end stage renal disease
- study protocol
- phase iii
- clinical trial
- newly diagnosed
- ejection fraction
- chronic kidney disease
- phase ii
- peritoneal dialysis
- left ventricular
- randomized controlled trial
- coronary artery disease
- extracorporeal membrane oxygenation
- patient reported outcomes
- atrial fibrillation